Sage Therapeutics has been granted a patent for compounds and salts useful in preventing and treating various CNS-related conditions. The method involves administering the compound to treat disorders such as anxiety, schizophrenia, multiple sclerosis, and more. GlobalData’s report on Sage Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sage Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sage Therapeutics, Anti-inflammatory anesthetics was a key innovation area identified from patents. Sage Therapeutics's grant share as of February 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11926646B2) discloses a method for treating Central Nervous System (CNS)-related conditions associated with NMDA-modulation. The conditions include a wide range such as adjustment disorder, anxiety disorder, cognitive disorder, mood disorder, schizophrenia, sleep disorder, substance-related disorder, and various others. The method involves administering an effective amount of a compound of Formula (B) to individuals in need of treatment.

The patent further details specific variations within the method, such as the value of 'n' in the compound formula, the nature of alkyl groups R1A and R1B, the formation of a 3-8 membered ring, and the characteristics of R2A, R2B, and R3 in the compound. Additionally, the patent covers the selection of the compound from a group of options and the use of pharmaceutically acceptable salts of the compound for treatment purposes. This patent provides a comprehensive framework for utilizing specific compounds to address a diverse range of CNS-related conditions, offering potential advancements in the field of neurological and psychiatric treatment modalities.

To know more about GlobalData’s detailed insights on Sage Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies